Dupixent (Dupilumab) Approved by the European Commission (EC) for Adolescents with Moderate-To-Intense Atopic Dermatitis

Atopic dermatitis (eczema) is a disease that makes skin red and itchy. It is a chronic inflammatory condition and a common cause of death. It is described by rashes, itching, skin lesions, and skin dryness. Uncontrolled eczema can have an emotional, physical, as well as psychosocial impact. It can cause anxiety, depression, and isolation. It also induces sleep disturbance. In spite of standard treatment, there is an unmet requirement for many adolescents. As per CEO of the International Alliance of Dermatology Patient Organizations, Christine Janus, medium-to-severe atopic dermatitis may affect many aspects of an adolescent’s life. It includes physical and emotional disorder. Organizations are focusing on adding new treatment options to control and manage a debilitating disease.

Regeneron Pharmaceuticals, Inc. and Sanofi S.A. announced that the EC extended marketing support for Dupixent. It covers children aged 6 to 11 with atopic dermatitis. Dupixent is the first biologic medication approved in the EU to treat patients. The consent is given based on data from the Liberty AD program. It combines pivotal phase three and an open-label continuation test. According to Investigator’s Global Assessment (IGA) score of 0 or 1, over ten times, Dupixent patients had clear skin as compared to placebo. Around 24% of patients received Dupixent achieved clear or almost clear skin compared to 2% with placebo. With this test can assess the effectiveness and safety of medicines in minors with controlled-to-severe atopic dermatitis. The trial evaluated with topical corticosteroids in 367 children — Aged 6 to 11 with eczema whose disease may not be adequately controlled with topical medications.

According to George D. Yancopoulos, a President and Chief Scientific Officer at Regeneron, teenagers with medium-to-severe atopic dermatitis have an accepted biologic remedy in the EU. This medicine can control persistent, debilitating illness such as itchiness. It also improves sleep. In the US, dupilumab is approved in children aged 12 years or more. It is used for moderate to severe atopic dermatitis and moderate to severe asthma. It is also recommended for adults with critical chronic rhino sinusitis with nasal polyposis.

Show More

Doris Maguire

Doris is the senior correspondent in the healthcare sector of LIVINGWITHED. He has been working in the world of writing for a few years, but he has been interested in health and medicine from even before. Before joining the editorial team of LIVINGWITHED, Doris had worked for a few health blogs. He is a big fan of books, movies and travels.

Related Articles